<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Janus Kinase 2 (JAK2) is a member of a family of four Janus Kinases, 2, and 3 and tyrosine kinase 2 </plain></SENT>
<SENT sid="1" pm="."><plain>Mutated JAK2 (V617F) has the ability to activate downstream signal transducer and activator of transcription (STAT)-mediated transcription in the absence of the ligand erythropoietin </plain></SENT>
<SENT sid="2" pm="."><plain>The autoinhibitory activity of JAK2 is disrupted by the presence of the V617F mutation </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0001428'>Somatic mutation</z:hpo> in JAK2 (V617F) gene has been reported in myeloid disorders </plain></SENT>
<SENT sid="4" pm="."><plain>This study reports the prevalence of JAK2V617F using amplification refractory mutation system (ARMS)-polymerase chain reaction in 246 Egyptian patients with different myeloid disorders and studied the relationship between the JAK2V617F mutation and parameters in peripheral blood </plain></SENT>
<SENT sid="5" pm="."><plain>The mutation was detected among 88 patients (35.8%) with different myeloid disorders </plain></SENT>
<SENT sid="6" pm="."><plain>JAK2V617F was found among 81.4% of <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>), 50% of <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e>, 46.1% of primary <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (PMF), 33.3% of philadelphia (Ph)-negative <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 33.3% of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>)/myeloproliferative <z:hpo ids='HP_0002664'>neoplasm</z:hpo> (MPN), and 50% of <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> associated with marked <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>-T) patients </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="35143">Hemoglobin</z:chebi> and white blood cells were significantly higher in the mutated group of MPN including <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>, <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e>, and PMF, whereas platelet counts were higher among the mutated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>, PMF, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>-T, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN group </plain></SENT>
<SENT sid="8" pm="."><plain>The identification of JAK2V617F mutations has raised the prospect of developing specific JAK2V617F inhibitors to treat mutated patients </plain></SENT>
</text></document>